Pharma BD Deal Intelligence
Option-structured entry into in vivo CAR-T immune reset
Full analysis, sources & comparables →Johnson & Johnson entered strategic agreements with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, with an exclusive option to acquire Sail. J&J makes total initial payments of $785 million, including a $465 million equity investment, plus $140 million in contingent development milestone payments; exercising the acquisition option would trigger an additional $2.58 billion payment. Sail's platform is designed to generate CAR-T cells directly in the body, avoiding ex vivo cell manufacturing. J&J guided to adjusted EPS dilution of roughly $0.18 in 2026 and $1.28 in 2027 assuming option exercise.
Autoimmune diseases driven by autoreactive B cells — including lupus, systemic sclerosis and myositis — have shown deep, drug-free remissions after autologous CD19 CAR-T "immune reset." Ex vivo CAR-T requires leukapheresis, lymphodepleting chemotherapy and complex manufacturing, which limits use in non-oncology populations. In vivo CAR-T aims to deliver the CAR construct directly to circulating T cells, removing cell manufacturing entirely.
In vivo CAR-T is a crowded emerging field: Capstan Therapeutics (acquired by AbbVie) uses targeted lipid nanoparticle-delivered mRNA to CD8+ T cells; Umoja Biopharma uses lentiviral VivoVec particles; Kelonia and Interius are also pursuing viral in vivo delivery. Sail differentiates on AI-designed circular eRNA payloads paired with targeted nanoparticle delivery.
Johnson & Johnson and Flagship-founded Sail Biomedicines announced a strategic collaboration to advance in vivo CAR-T therapies for immune-mediated disease, initially in autoimmune indications. Sail receives $785 million in initial payments — including a $465 million equity investment — plus $140 million in development milestones, and J&J takes an exclusive option to acquire Sail for an additional $2.58 billion.
Sail Biomedicines confirmed the collaboration pairs its AI-driven eRNA design and targeted nanoparticle delivery platform with J&J development, manufacturing and commercialization capability, focused first on autoimmune conditions.
J&J buys a call option on in vivo CAR-T rather than the asset itself: real money up front ($785M including equity) but the $2.58B acquisition price is only paid if the platform delivers. The science is preclinical and the competitive field (Capstan/AbbVie, Umoja, Kelonia) is crowded.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Sail Biomedicines, Inc. (this deal) | 2026 | $3.4B | 65 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2026 deals · Johnson & Johnson deals